External Guide Sequences

Drug Profile

External Guide Sequences

Latest Information Update: 29 Aug 2002

Price : $50

At a glance

  • Originator Yale University
  • Class
  • Mechanism of Action Ribonuclease P stimulants; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 29 Aug 2002 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
  • 29 Aug 2002 Nexell is winding down its operations and discontinuing development of its therapeutic pipeline
  • 25 Jun 2001 No-Development-Reported for Hepatitis B in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top